Is Isotretinoin (Accutane) Overprescribed?
Yes, Isotretinoin Is Overprescribed. The Decision to Take It Should Be Made Only After Careful Consideration.
The Essential Information
The current medical research shows that isotretinoin (Accutane®), while extremely effective for severe acne, is overprescribed for the treatment of mild-to-moderate acne.
Isotretinoin is an oral medication that affects the entire body, changing not only the skin, but also potentially other parts of the body, forever.
Be Your Own Advocate: You only get one body. If you have severe, widespread, and scarring acne, isotretinoin may be an important option for you to consider. But if you suffer from less severe acne, make sure you exhaust other options before you take a medication that will change your body forever.
Isotretinoin is an oral medication derived from Vitamin A that is normally used to treat severe nodular and cystic acne. Isotretinoin is taken orally once a day, normally for 15-20 weeks, with a meal that contains an adequate amount of dietary fat to aid in absorption.
Even though isotretinoin is effective1,2, it can come with severe and potentially long-lasting side effects. Because of these side effects, the FDA developed strict conditions under which doctors should prescribe the drug, and these conditions have become ever more rigorous over time as the severity of isotretinoin side effects come to light.
In spite of these guidelines, research regarding the prescription of isotretinoin shows that it is often prescribed to patients that do not meet these strict conditions.
The FDA Sets Strict Guidelines for the Prescription of Isotretinoin
Currently the FDA is responsible for establishing and implementing guidelines controlling isotretinoin prescription, but physicians can prescribe any drug as they see fit regardless of these official guidelines.
The current guidelines state that:
- Isotretinoin should only be used to treat severe acne that has not responded to at least one previous six to eight week treatment course of another acne therapy.3-5
- Isotretinoin should not be used to treat mild-to-moderate acne.4-5
- Isotretinoin should never be prescribed as a first line of therapy.4-5
- Isotretinoin should never be offered to children under the age of 12.2,5
- Chemical peeling treatments should be avoided during and six months following isotretinoin treatment.5
- The beginning dosage of isotretinoin should be 0.5 mg per kg of body weight (0.5 mg per 2.2 pounds).4-5
Against Recommendations, Doctors Sometimes Prescribe Isotretinoin for Mild-to-Moderate Acne
Istoretinoin hit the market in 1982. Despite increased FDA restrictions, prescriptions for isotretinoin have dramatically increased over the past 30+ years.
The last study examining the number of provided prescriptions looked at the years between 1982 and 2000, and found a dramatic uptick in the number of prescriptions written during this period. The researchers noted that this increase was due to more doctors prescribing isotretinoin for mild-to-moderate acne. Isotretinoin prescriptions for severe acne actually decreased during this period.6
Expand to read details of study
While providers prescribed an average of 800,000 isotretinoin prescriptions per year between 1983 and 1993, by 2000 providers were writing nearly 2 million prescriptions per year, amounting to a 250% increase compared with 1983.6 The researchers attributed this increase with physicians using isotretinoin to treat mild-to-moderate acne, which rose from 31% in 1993 to 49% in 2000. While isotretinoin prescriptions for mild-to-moderate acne increased, the total prescriptions for severe acne decreased from 63% to 46%. Therefore, researchers attributed the 250% increase in total isotretinoin prescriptions to the treatment of mild-to-moderate acne and not for severe acne as the current regulatory guidelines advise.6
High Relapse Rates
There is further controversy over the increased prescribing of isotretinoin due to its potential for limited long-term effectiveness, especially in people with more severe acne and in males.2 The idea of the isotretinoin achieving a cure can be misleading. The relapse rate after a course of isotretinoin therapy can be anywhere between 15-60% depending on the severity of acne, duration of treatment, and dosage provided.7
Scientists believe that relapses are underreported and thus the true relapse rate is higher than patients and doctors may believe. For example, some people with severe acne may overlook a few small blemishes following isotretinoin treatment because these spots are considered insignificant and therefore patients do not report this renewed, yet lesser, outbreak as a relapse.2
The Bottom Line: Doctors Overprescribe Isotretinoin
The current research indicates that isotretinoin, while extremely effective, is overprescribed for the treatment of mild-to-moderate acne.8,9 Upon examining the severe side effects and potential for relapse, it becomes clear that doctors should take care in closely following the restrictive guidelines regarding prescription.
In order to receive the best therapy course for your acne type, it is crucial to discuss all available treatment options with a medical professional. Finally, it is always important to speak openly with your doctor regarding the severity of your acne, risks, side effects, and alternatives when considering a course of isotretinoin therapy. Research suggests that doctors sometimes fail to discuss the serious side effects of isotretinoin with their patients because of time constraints during medical appointments.10 Be your own advocate and make sure to ask about any concerns you have.
- Katsambas, A. & Papakonstantinou, A. Acne: systemic treatment. Clin. Dermatol. 22, 412-418 (2004). https://www.ncbi.nlm.nih.gov/pubmed/15556728
- Layton, A. The use of isotretinoin in acne. Dermatoendocrinol. 1, 162-169 (2009). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835909/
- Goldsmith, L. A. et al. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J. Am. Acad. Dermatol. 50, 900-906 (2004). https://www.ncbi.nlm.nih.gov/pubmed/15153892
- Goh, C. L. et al. South-East Asia study alliance guidelines on the management of acne vulgaris in South-East Asian patients. J. Dermatol. 42, 945-953 (2015). https://www.ncbi.nlm.nih.gov/pubmed/26211507
- Layton, A. M., Dreno, B., Gollnick, H. P. & Zouboulis, C. C. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J. Eur. Acad. Dermatol. Venereol. 20, 773-776 (2006). https://www.ncbi.nlm.nih.gov/pubmed/16898895
- Wysowski, D. K., Swann, J. & Vega, A. Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. Journal of the Am. Acad. Dermatol. 46, 505-509 (2002). https://www.ncbi.nlm.nih.gov/pubmed/11907498
- Morales-Cardona, C. & Sánchez-Vanegas, G. Acne relapse rate and predictors of relapse following treatment with oral isotretinoin. Actas Dermosifiliogr. 104, 61-66 (2013). https://www.ncbi.nlm.nih.gov/pubmed/22795452
- Evaristo, L. S. B. F. & Bagatin, E. Use of oral isotretinoin to treat acne in the public system: a hospital-based retrospective cohort. Sao Paulo Med J 137, 363-368 (2019). https://pubmed.ncbi.nlm.nih.gov/31691769/
- O'Donnell, J. Overview of existing research and information linking isotretinoin (accutane), depression, psychosis, and suicide. Am J Ther 10, 148-159 (2003). https://pubmed.ncbi.nlm.nih.gov/12629595/
- Kokandi AA. Trends and opinion of isotretinoin use for acne treatment by dermatologists in western area of Saudi Arabia: A cross-sectional survey. Int Arch BioMed Clin Res 3, 10-15 (2017). https://iabcr.org/index.php/iabcr/article/view/44
You May Like